Generate Biomedicines

Generate describes a randomized placebo-controlled first-in-human GB-0669 study enrolling 51 healthy adults, with 36 receiving the AI-designed antibody, reporting tolerability, pharmacokinetic and neutralization observations.

Generate Biomedicines has advanced generatively designed protein therapeutics into development and clinical-stage programs.

Generate Biomedicines has advanced generatively designed protein therapeutics into development and clinical-stage programs.

Generate operates a closed-loop generate-build-measure-learn platform that combines generative algorithms with at-scale protein synthesis and experimental measurement; AI-designed medicines from this platform have reached human clinical studies, including peer-reviewed first-in-human results for GB-0669.

Generate develops machine-learning platforms for programmable protein therapeutics and biological design.

Generate develops machine-learning platforms for programmable protein therapeutics and biological design.

Generate disclosed a $273 million Series C in September 2023 and nearly $700 million in equity financing since 2020. This historical capital-backing event is independent of its general AI, laboratory and clinical execution capabilities; the announcement's runway expectation is not treated as current liquidity.

Generate combines AI research, wet-lab biology, drug development and clinical execution capabilities.

Generate combines AI research, wet-lab biology, drug development and clinical execution capabilities.

Generate's Chroma documentation specifies diffusion-based protein generation, random graph neural networks for long-range reasoning, equivariant 3D layers and constraint-conditioned sampling; it also provides model code, weights and an interactive notebook.

ML and generative modeling skills transfer broadly, while protein therapeutics and wet-lab specialization constrain full portability.

ML and generative modeling skills transfer broadly, while protein therapeutics and wet-lab specialization constrain full portability.